Survodutide

BI 456906

Add to protocol

Build with Survodutide

Compare prices

Pharmacies & vendors

Calculate dosing

Reconstitution

Overview

Survodutide is a dual GLP-1 / glucagon receptor agonist from Boehringer Ingelheim and Zealand Pharma. In Phase III for obesity and MASH.

Mechanism of Action

GLP-1R + GCGR co-agonism, similar to mazdutide/retatrutide class. Glucagon arm drives energy expenditure alongside GLP-1-mediated appetite suppression.

Research Summary

Phase II obesity trial showed ~19% weight loss at 46 weeks (highest dose). Phase III LIBERATE program ongoing.

Dosing Information

Typical Dose

2.4–6 mg

Frequency

Weekly

Route

SubQ

Notes

Research chemical outside clinical trials.

Reported Side Effects

Nausea
Vomiting
Diarrhea
Fatigue

Contraindications

Personal or family history of medullary thyroid carcinoma
Pregnancy

Track your Survodutide protocol

Build a protocol with Survodutide, schedule blood work for key biomarkers, and track your results.

Build Protocol with Survodutide

This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.